Comparison of therapeutic effect of prostatan (nettle) and pumpkin extract in a patient with benign prostatic hyperplasia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210602051475N1

Enrollment

100

Registered

2021-06-21

Start date

2021-06-02

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Enlarged prostate

Interventions

Intervention 1: Control group: standard treatment includes tamsulosin 0.4 mg capsules daily for two months. Intervention 2: Intervention group: tamsulosin capsules 0.4 mg daily and pumpkin drops 10 dr

Eligibility

Sex/Gender

Male

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 50 years old Benign prostate enlargement Administrative detention Frequent urination

Exclusion criteria

Exclusion criteria: Existence of urological disease other than benign prostate enlargement Need immediate surgical intervention for treatment Use of BPH-related drugs (stimulants and aggravators) in the last six months

Design outcomes

Primary

Measure	Time frame
Decreased PSA levels during treatment. Timepoint: In the times before the intervention (0), two weeks, four weeks and eight weeks after the intervention, the questionnaire will be filled in by the participants in the project. Method of measurement: World Standard Scale for Symptoms of Prostate Hyperplasia and Uflometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReyhaneh Sedigh

Sabzevar University of Medical Sciences

rsedigh97@gmail.com+98 51 4401 8101

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026